Bevacizumab-related arterial hypertension as a predictive marker in metastatic colorectal cancer patients

被引：0
|
作者：
Alfonso De Stefano
Chiara Carlomagno
Stefano Pepe
Roberto Bianco
Sabino De Placido
机构：
[1] Università degli Studi di Napoli Federico II,Dipartimento di Endocrinologia ed Oncologia Molecolare e Clinica
来源：
Cancer Chemotherapy and Pharmacology | 2011年 / 68卷
关键词：
Bevacizumab; Arterial hypertension; Metastatic colorectal cancer; Predictive marker;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1207 / 1213
页数：6
相关论文
共 50 条
  • [31] Microsatellite instability: a predictive marker in metastatic colorectal cancer?
    Des Guetz, Gaetan
    Uzzan, Bernard
    Nicolas, Patrick
    Schischmanoff, Olivier
    Morere, Jean-Francois
    TARGETED ONCOLOGY, 2009, 4 (01) : 57 - 62
  • [32] Microsatellite instability: a predictive marker in metastatic colorectal cancer?
    Gaëtan Des Guetz
    Bernard Uzzan
    Patrick Nicolas
    Olivier Schischmanoff
    Jean-François Morere
    Targeted Oncology, 2009, 4 : 57 - 62
  • [33] Hypertension as a Predictive Factor of Effect of Bevacizumab in Treatment of Colorectal Cancer
    Horinouchi, Yuya
    Sakurada, Takumi
    Nakamura, Toshimi
    Tajima, Soichiro
    Nishisako, Hirotaka
    Abe, Shinji
    Teraoka, Kazuhiko
    Kujime, Toshihide
    Kawazoe, Kazuyoshi
    Minakuchi, Kazuo
    YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 2011, 131 (08): : 1251 - 1257
  • [34] CORRELATION BETWEEN DEVELOPMENT OF HYPERTENSION AND EFFICACY IN METASTATIC COLORECTAL CANCER PATIENTS TREATED WITH BEVACIZUMAB
    Horinouch, Y.
    Sakurada, T.
    Nakamura, T.
    Mori, T.
    Konaka, K.
    Tajima, S.
    Abe, S.
    Teraoka, K.
    Kujime, T.
    Kawazoe, K.
    Houchi, H.
    Minakuchi, K.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2011, 109 : 57 - 57
  • [35] Correlation between development of hypertension and efficacy in metastatic colorectal cancer patients treated with bevacizumab
    Horinouchi, Y.
    Sakurada, T.
    Nakamura, T.
    Mori, T.
    Konaka, K.
    Tajima, S.
    Abe, S.
    Teraoka, K.
    Kujime, T.
    Kawazoe, K.
    Houchi, H.
    Minakuchi, K.
    10TH CONGRESS OF THE EUROPEAN ASSOCIATION FOR CLINICAL PHARMACOLOGY AND THERAPEUTICS (EACPT), 2011, : 105 - 108
  • [36] Carbonic anhydrase 9 is a predictive marker of survival benefit from lower dose of bevacizumab in patients with previously treated metastatic colorectal cancer
    Hong, Yong Sang
    Cho, Hyeon Jin
    Kim, Sun Young
    Jung, Kyung Hae
    Park, Ji Won
    Choi, Hyo Seong
    Oh, Jae Hwan
    Kim, Byung Chang
    Sohn, Dae Kyung
    Kim, Dae Yong
    Chang, Hee Jin
    BMC CANCER, 2009, 9 : 246
  • [37] Carbonic anhydrase 9 is a predictive marker of survival benefit from lower dose of bevacizumab in patients with previously treated metastatic colorectal cancer
    Yong Sang Hong
    Hyeon Jin Cho
    Sun Young Kim
    Kyung Hae Jung
    Ji Won Park
    Hyo Seong Choi
    Jae Hwan Oh
    Byung Chang Kim
    Dae Kyung Sohn
    Dae Yong Kim
    Hee Jin Chang
    BMC Cancer, 9
  • [38] Hypertension as a Predictive Marker for Bevacizumab in Metastatic Breast Cancer: Results from a Retrospective Matched-pair Analysis
    Gampenrieder, Simon Peter
    Romeder, Franz
    Muss, Claudia
    Pircher, Magdalena
    Ressler, Sigrun
    Rinnerthaler, Gabriel
    Bartsch, Rupert
    Sattlberger, Claudia
    Mlineritsch, Brigitte
    Greil, Richard
    ANTICANCER RESEARCH, 2014, 34 (1A) : 227 - 233
  • [39] Role of arterial hypertension as a predictive marker for bevacizumab efficacy in recurrent glioblastoma - a prospective analysis
    Wagner, Claudia C.
    Held, Ulrike
    Kofmehl, Reto
    Battegay, Edouard
    Zimmerli, Lukas
    Hofer, Silvia
    ACTA ONCOLOGICA, 2014, 53 (04) : 572 - 575
  • [40] Treatment with bevacizumab in patients with metastatic colorectal cancer (mCRC)
    Ocvirk, Janja
    Rebersek, Martina
    Boc, Marko
    Motara, Maja Ebert
    Mesti, Tanja
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345